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Partial suppression of mitochondrial oxidative phosphorylation and the concurrent 
activation of aerobic glycolysis is a hallmark of proliferating cancer cells. Overexpression 
of the ATPase inhibitory factor 1 (IF1), an in  vivo inhibitor of the mitochondrial ATP 
synthase, is observed in most prevalent human carcinomas favoring metabolic rewiring 
to an enhanced glycolysis and cancer progression. Consistently, a high expression of 
IF1 in hepatocarcinomas and in carcinomas of the lung, bladder, and stomach and in 
gliomas is a biomarker of bad patient prognosis. In contrast to these findings, we have 
previously reported that a high expression level of IF1 in breast carcinomas is indicative 
of less chance to develop metastatic disease. This finding is especially relevant in the 
bad prognosis group of patients bearing triple-negative breast carcinomas. To investi-
gate the molecular mechanisms that underlie the differential behavior of IF1 in breast 
cancer progression, we have developed the triple-negative BT549 breast cancer cell line 
that overexpresses IF1 stably. When compared to controls, IF1-cells partially shut down 
respiration and enhance aerobic glycolysis. Transcriptomic analysis suggested that 
migration and invasion were specifically inhibited in IF1-overexpressing breast cancer 
cells. Analysis of gene expression by qPCR and western blotting indicate that IF1 overex-
pression supports the maintenance of components of the extracellular matrix (ECM) and 
E-cadherin concurrently with the downregulation of components and signaling pathways 
involved in epithelial to mesenchymal transition. The overexpression of IF1 in breast can-
cer cells has no effect in the rates of cellular proliferation and in the cell death response to 
staurosporine and hydrogen peroxide. However, the overexpression of IF1 significantly 
diminishes the ability of the cells to grow in soft agar and to migrate and invade when 
compared to control cells. Overall, the results indicate that IF1 overexpression despite 
favoring a metabolic phenotype prone to cancer progression in the specific case of breast 
cancer cells also promotes the maintenance of the ECM impeding metastatic disease. 
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These findings hence provide a mechanistic explanation to the better prognosis of breast 
cancer patients bearing tumors with high expression level of IF1.
Keywords: mitochondria, aTP synthase, aTPase inhibitory factor 1, gene expression analysis, breast cancer, 
extracellular matrix, cellular migration, cellular invasion
inTrODUcTiOn
Partial suppression of ATP production by mitochondrial oxidative 
phosphorylation and the concurrent metabolic repro gramming 
of the cell to an enhanced aerobic glycolysis is a hallmark fea-
ture of proliferating normal, cancer, and stem cells (1–6). This 
switch in metabolic phenotype warranties that a fraction of the 
glucose carbon skeletons available rather than being oxidize to 
CO2 could supply the anabolic precursors and reducing power 
that are needed to sustain proliferation (7–10). The ATP synthase 
is the enzyme that utilizes the proton electrochemical gradient 
generated by respiration for the synthesis of ATP (11, 12). Several 
mechanisms promote the rewiring of metabolism in human car-
cinomas at the level of the ATP synthase (13, 14). The main of the 
ones described are (i) the partial downregulation of the expres-
sion of the catalytic subunit of the ATP synthase (β-F1-ATPase) 
(7, 15, 16), which in solid carcinomas is exerted by the specific 
repression of β-F1-ATPase mRNA translation (14, 17, 18) and 
in chronic myeloid leukemia by hypermethylation and silencing 
of the promoter of the ATP5B gene (19) and (ii) by the inhibition 
of the activity of the ATP synthase mediated by the overexpres-
sion of the ATPase inhibitory factor 1 (IF1) (20–22).
The activity of IF1 as an inhibitor of the ATP synthase is 
regulated by matrix pH under conditions of mitochondrial 
de-energization (13, 23–25) and by the phosphorylation of S39 
under several physiological situations such as progression through 
the cell cycle, hypoxia, rapid changes in metabolic demand, and 
cancer (26). In the specific case of breast carcinomas, we have 
recently described that IF1 is found essentially in its dephospho-
rylated form and hence able to bind and inhibit the ATP synthase 
activity of the enzyme (13, 26). Remarkably, the overexpression 
of IF1 in different cancer cells promotes the acquisition of a pro-
oncogenic phenotype by inducing metabolic reprogramming to 
an enhanced glycolysis (21, 22, 27). Moreover, overexpression of 
IF1 triggers in mitochondria a concurrent reactive oxygen spe-
cies (ROS) signal that switches on the NF-κB pathway favoring 
invasion and cell survival in colon and lung cancer cells (21, 27). 
Consistently, a high expression level of IF1 in human hepatocarci-
nomas (28) and in carcinomas of the lung (29), bladder (30), and 
stomach (31) and in gliomas (32) is a biomarker of bad prognosis 
for the patients. In sharp contrast to these findings, a high expres-
sion level of IF1 in breast carcinomas positively correlates with 
less chance to develop metastatic disease; in other words, it is 
a biomarker of good prognosis for breast cancer patients (21).
In this study, we have questioned the molecular bases that sus-
tain why a high expression level of IF1 in breast carcinomas yields 
a biomarker of good prognosis for the patients despite favoring 
a phenotype prone to oncogenesis (21). The transcriptomic and 
phenotypic analysis of breast cancer cells expressing high levels of 
IF1 supports that a good prognosis in these patients is based on 
the poorer potential of the cells to migrate and invade, as a result 
of a better maintenance of the extracellular matrix (ECM) and 
epithelial phenotype.
MaTerials anD MeThODs
Patient specimens and iF1 Determinations
A collection of anonymized frozen tissue sections obtained 
from surgical specimens of 93 patients who had an operation 
for invasive breast carcinoma at the Hospital Universitario La 
Paz (HULP) between 1991 and 2000 was interrogated in previ-
ous studies for the expression of proteins of energy metabolism 
(33, 34). The expression of IF1 in these breast biopsies and 
the study of its correlation with patients’ survival have been 
partially described previously (21). The Cancer Survey Tissue 
Microarray (OriGene, Rockville, MD, USA) containing sections 
of formalin-fixed normal and tumor specimens of the breast 
were immunostained using the monoclonal anti-IF1 (1:200) 
antibody (22). Sections were counterstained with hematoxylin. 
Patient’s medical records were reviewed and identifiers coded to 
protect patient confidentiality.
generation of cell lines and cell cultures
The breast cancer BT549-luc cell line was kindly provided 
by Dr. Murakami from the Japanese Collection of Research 
Bioresources Cell Bank (#JCRB1373). The BT549-luc cell line is 
a triple-negative breast cancer cell that is estrogen receptor nega-
tive, progesterone receptor negative, and lacks epidermal growth 
factor receptor 2 (Her2/neu) overexpression. Cells were cultured 
in RPMI-1640 medium supplemented with 15% FBS and 1% 
penicillin/streptomycin in a 5% CO2 incubator. The pCDH-
CMV-MCS-EF1-RFP  +  Puro cDNA Cloning and Expression 
Vector (SBI#CD616B-2) (SBI System Biosciences) was used 
to establish cells overexpressing the human ATPase IF1. The 
plasmid also expresses RFP for selection purposes. The human 
IF1 insert was obtained from the pCMV-Sport6-IF1 plasmid (22) 
by digestion with the NotI and EcoRI restriction sites and ligated 
with the linearized plasmid to generate the pCDH-CMV-MCS-
EF1-RFP + PURO-IF1 plasmid. All the constructs were checked 
by sequencing. Stable cell lines derived by transfection with the 
pCDH-CMV-MCS-EF1-RFP  +  PURO empty vector (control, 
CRL) and the pCDH-CMV-MCS-EF1-RFP +  PURO-IF1 were 
generated using lentivirus. For lentiviral transfection, viral par-
ticles were produced in HEK293T  cells. They were cultured in 
DMEM 10% FBS. After the transfection of BT549 cells, stable 
transfectants were selected by adding 6 µg/ml puromycine (Invit-
rogen; Thermo Fisher Scientific, Inc.) to the growth medium.
cellular lysis and Western Blotting
Cell lysis was performed with RLN-T buffer (RLN buffer plus 
0.5% Triton X-100 and the complete protease inhibitors cocktail 
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EDTA-free; Roche) at 20 × 106 cells/ml for 5 min on ice. Extracts 
were centrifuged at 11,000 × g for 15 min at 4°C. The primary 
antibodies used were as follows: anti-IF1 (1:200) (22), e-cadherin 
(1:250, BD Biosciences), β1 integrin (1:2, kindly provided by 
Carlos Cabañas, CBMSO), β-catenin (1:500, BD Biosciences), 
vimentin (1:1,000, Cell Signaling), NF-κB p65 (1:1,000, Abcam), 
pIKBα (1:500, Cell Signaling), IKBα (1:1,000, Cell Signaling), 
α-tubulin (1:3,000, Sigma-Aldrich), β-F1-ATPase (1:25,000) 
and Hsp60 (1:2,000) from Ref. (35), SDH-B (1:500, Invitrogen), 
α-F1-ATPase (1:1,000, Molecular Probes), Core 2 of complex III 
(1:500, Abcam), MTCO2 (1:500, Abcam), VDAC (1:500, Abcam), 
and PYGM (1:1,000, Abcam).
subcellular Fractionation
Mitochondrial isolation was performed according to Acin-Perez 
et al. (36). In brief, cells were washed with PBS. Cellular pellets 
were homogenized in a glass–teflon homogenizer with seven vol-
umes of hypotonic buffer (83 mM sucrose, 10 mM MOPS pH 7.2). 
 After homogenization, the same volume of hypertonic buffer 
(250 mM sucrose, 30 mM MOPS pH 7.2) was added and nuclei 
and unbroken cells were removed by centrifugation at 1,000 × g. 
Mitochondria were obtained by centrifugation at 12,000 × g and 
washed in buffer A (320 mM sucrose, 1 mM EDTA, 10 mM Tris–
HCl pH 7.4). Cytosolic fraction was collected in the supernatant. 
Mitochondria were further purified by centrifugation through a 
0.8 M sucrose cushion in 10 mM Tris–HCl pH 7.5 0.1% BSA. 
Cellular, mitochondrial, and cytosolic proteins were loaded on 
SDS-PAGE, transferred onto nitrocellulose membranes, and 
immunoblotted against diverse antibodies.
Determination of the h+-aTP synthase 
activity and cellular aTP
The ATP synthetic activity was determined in digitonin-
permeabilized cells following the detailed protocol in Ref. (37). 
Inhibition of the synthase activity of the H+-ATP synthase was 
accomplished by the addition of 30 µM oligomycin (OL). Cellular 
ATP concentrations were determined using the ATP Biolumines-
cence Assay Kit CLS II (Roche) following the manufacturer’s 
instructions.
glycolysis, cellular respiration,  
and rOs Production
The initial rates of lactate production were determined as an 
index of glycolysis by enzymatic determination of lactate con-
centrations in the culture medium (38). Oxygen consumption 
rates were determined in an XF24 Extracellular Flux Analyzer 
(Seahorse Bioscience) (22). Cells were seeded in the micro-
plates, and incubated at 37°C and 5% CO2 for 24  h. The final 
concentration and order of injected substances was 6  µM OL, 
0.75  mM DNP (2,4-dinitrophenol), 1  µM rotenone, and 1  µM 
antimycin. The intracellular production of hydrogen peroxide 
was monitored by flow cytometry using 5  µM 6-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate (DCFH2-DA) (Molecular 
Probes, Eugene, OR, USA) and incubated 30 min at 37°C (27). 
Cells were analyzed in a BD FACScan. For each analysis, 10,000 
events were recorded.
gene array hybridization
Total RNA was extracted from BT549 cells using Trizol 
(Invitrogen, Carlsbad, CA, USA) followed by the Qiagen RNeasy 
(Qiagen, Valencia, CA, USA). Each RNA preparation was tested 
for degradation using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA, USA). Total RNA (200  ng) was 
amplified using One-Color Low Input Quick Amp Labeling Kit 
(Agilent Technologies) and purified with RNeasy Mini Kit 
(Qiagen). Preparation of probes and hybridization was performed 
as described in One-Color Microarray Based Gene Expression 
Analysis Manual Ver. 6.5, Agilent Technologies. Briefly, for each 
hybridization, 600 ng of Cy3 probes were mixed and added to 
5  µl of 10× blocking agent, 1  µl of 25× fragmentation buffer, 
and nuclease-free water in a 25-µl reaction, incubated at 60°C 
for 30  min to fragment RNA, and stopped with 25  µl of 2× 
hybridization buffer. The samples were placed on ice and quickly 
loaded onto arrays, hybridized at 65°C for 17 h in a hybridization 
oven, and then washed in GE Wash Buffer 1 at room temperature 
(1 min) and in GE Wash Buffer 2 at 37°C (1 min). Arrays were 
dried by centrifugation at 2,000 rpm for 2 min. Slides were Sure 
Print G3 Agilent 8x60K Human (G4852A-028004). Images were 
captured with an Agilent Microarray Scanner and spots quanti-
fied using Feature Extraction Software (Agilent Technologies). 
Background correction and normalization of expression data 
were performed using LIMMA (39, 40). Linear model methods 
were used for determining differentially expressed genes. Each 
probe was tested for changes in expression over replicates by 
using an empirical Bayes moderated t-statistic (39). To control the 
false discovery rate p-values were corrected by using the method 
of Benjamini and Hochberg (41). The expected false discovery 
rate was controlled to be <5%. Hybridizations and statistical 
analysis were performed by the Genomics Facility at Centro 
Nacional de Biotecnologia (Madrid, Spain).
gene Data analysis
A gene list was made by selecting genes with a fold change ≥1.5 
or ≤−1.5 between control and IF1-overexpressing cells. A cor-
rected p-value ≤0.05 was considered statistically significant. 
GeneCodis3 tool was used to perform gene set enrichment analy-
sis with GeneCodis (42) to infer the main biological functions 
associated with IF1 overexpression using KEGG and Panther 
pathways enrichments. Gene set enrichment by Ingenuity Path-
way Analysis (Qiagen) was also used to determine the specific 
canonical signaling pathways and related diseases and functions 
affected. A Fisher’s exact right-tailed test identified significantly 
enriched pathways, and a z score was computed to determine 
whether the pathway was activated or inhibited at each stage.
Quantitative reverse Transcription 
Polymerase chain reaction (Pcr) 
analysis
Reverse transcription reactions were performed using 1  µg 
of total RNA and the High Capacity Reverse Transcription 
Kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). 
Real-time PCR was performed with an ABI PRISM 7900HT 
SDS (Applied Biosystem) and Power SYBR Green PCR 
FigUre 1 | expression of inhibitory factor 1 (iF1) in human breast 
carcinomas. (a) Representative immunohistochemistry of IF1 expression  
in normal and tumor tissue of the breast. (B) The histograms show the 
Kaplan–Meier 5-year overall and disease-free survival rates (mean ± SEM)  
for the cohort of 93 breast cancer patients stratified by the tumor expression 
level of IF1 (21). (c) Same as above for the 18 hormonal receptor negative 
subgroup of carcinomas contained in the cohort. Protein samples from 
normal and tumor breast samples were analyzed by western blot for the 
expression level of IF1 as indicated previously (21). *p = 0.03 and *p = 0.001 
show the log-rank test p-value in (B) and (c), respectively.
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Master Mix (Applied Biosystems). The following primers 
were used: ACTA2 (NM_001141945), DCN (NM_001920), 
ITGB1 (NM_002211), POSTN (NM_001135934), TGFB3 
(NM_003239), SERPINB7 (NM_001040147), SERPINB11 
(NM_080475), VCAN (NM_001126336), and WNT2B (NM_ 
004185). All primers provided by Sigma-Aldrich.
cellular Proliferation and cell  
Death assays
Cellular proliferation was determined by counting the number of 
cells/well after 24, 48, and 72 h of culture. For cell death assays, 
30,000 cells/well were seeded and treated with 1 µM staurosporine 
(STS) or 120  µM hydrogen peroxide during 24  h. Cell death 
was determined by flow cytometry after staining with annexin V 
(ApoScreen FITC; Southern #10010-02) (27).
soft agar, Wound healing,  
and invasion assays
For soft agar assay, 2,000 cells were added to 750 µl of complete 
growth media with 0.5% agarose and layered onto a 750 µl bed 
of complete growth media plus 0.7% of agar on a 12-well plate. 
After 5  weeks, viable colony numbers were stained with 0.5% 
crystal violet in 4% paraformaldehyde and counted using ImageJ 
software. For wound healing assays, confluent cell monolayers 
were mechanically disrupted with a sterile pipette tip to produce a 
clean uniform scratch. The wells were photographed every 30 min. 
Gap distances were analyzed with ImageJ software. Corning 
BioCoat Matrigel Invasion Chambers were used to quantify the 
cellular invasive capacity. A total of 2 ×  104 cells were seeded 
in 1% FBS and chemoattraction perform during 72 h in 20% FBS.
statistical analysis
The results shown are the means ± SEM of four to six biological 
replicates. Statistical analysis was performed by Student’s t-test, 
Mann–Whitney U test, and/or Kruskal–Wallis as appropriate. 
Tests were calculated using the SPSS 13.0 software package 
(IBM, Chicago, IL, USA). Survival curves were derived from 
Kaplan–Meier estimates and compared by log-rank test. Statistical 
tests were two sided at the 5% level of significance.
resUlTs
Overexpression of iF1 in human  
Breast carcinomas
We have previously documented in a large cohort of breast cancer 
patients (33) that IF1 is highly overexpressed in breast carcino-
mas (21) [for details, see supplemental Table 1 in Ref. (21)]. 
These results have been further confirmed in another large 
cohort of breast carcinomas (43). Figure 1A provides an illus-
trative example of the changes taking place in IF1 expression in 
breast by oncogenesis. The normal breast tissue shows negligible 
expression of IF1, whereas a very high expression level of the 
protein is observed in the carcinomas. Figure  1B shows that 
the tumor expression level of IF1 has no relevant influence on 
the 5-year overall survival rate in breast cancer patients. How-
ever, when the content of IF1 in the carcinoma is high (21), it 
significantly associates with an increase in disease-free survival 
of the patients (Figure  1B). The association of high IF1 levels 
with a lesser chance to develop metastatic disease is magnified 
in the poor prognosis group of triple-negative breast carcinomas 
(Figure 1C) (21). Overall, these findings suggest that high IF1 
levels in breast carcinomas in some way correlate with a decrease 
of metastasis despite supporting a pro-oncogenic metabolic 
phenotype (21, 22, 27).
energy Metabolism of iF1-Overexpressing 
BT549 cancer cells
In order to investigate the molecular basis of this paradox, we 
developed stable IF1-overexpressing breast cancer cells (IF1- 
cells). For this purpose, we used the triple-negative breast 
cancer cell line BT549-luc. After transfection and selection, the 
overexpression of IF1 was confirmed both by immunoblotting 
(Figure 2A) and immunofluorescence microscopy (Figure 2B). 
The overexpressed transgene was localized in mitochondria 
(Figures  2B,C). Consistent with previous findings in transient 
expression experiments (21), the lentivirus-driven overexpres-
sion of IF1 significantly diminished the rates of cellular respira-
tion (Figure  2D). Moreover, and when compared to controls, 
the rates of glycolysis were significantly augmented in IF1-cells 
(Figure  2E), further supporting that IF1 is interfering with 
the mitochondrial production of ATP by the ATP synthase 
(21, 22, 27). In fact, the expression of IF1 partially inhibited 
FigUre 2 | continued
5
García-Ledo et al. IF1 Impairs Breast Cancer Invasion
Frontiers in Oncology | www.frontiersin.org April 2017 | Volume 7 | Article 69
FigUre 2 | continued  
energy metabolism of inhibitory factor 1 (iF1)-overexpressing BT549-luc cells. (a,B) The histograms show the quantification of IF1 expression in two 
different biological replicates (1 and 2) by immunoblotting (a) and immunofluorescence microscopy (B). Nuclei: blue, DAPI staining; transfection marker: red 
fluorescent protein, RFP; mitochondria: green fluorescence, IF1. (c) Overexpressed IF1 is exclusively localized in mitochondria (Mit). T.P., total cellular protein; Cyt, 
cytosolic protein; PYGM, glycogen phosphorylase; βF1, β-F1-ATPase. (D) Rates of basal, oligomycin (OL) sensitive, and maximum respiration determined in the X24 
Seahorse Flux Analyzer. (e) Initial rates of lactate production in the absence (−) or presence (+) of 6 µM OL. (F) Plot, kinetic representation of the linear production of 
ATP in relative light units (RLU) in CRL (blue) and IF1 (red) expressing digitonin-permeabilized cells. The inhibition of ATP synthase activity by the addition of 30 µM 
OL is shown in red. Histograms shows the ATP synthetic activity. (g) Cellular ATP concentration in CRL and IF1-overexpressing cells. (h) Cellular hydrogen peroxide 
detection with DCFH2-DA. CRL, control; IF1, IF1-overexpressing cells; a.u., arbitrary units. (i) Representative western blots of the expression of mitochondrial 
proteins (α-F1-ATPase, β-F1-ATPase, SDH-B, Core 2, COII, VDAC, Hsp60, and IF1) and tubulin in two different replicates of CRL and IF1-overexpressing cells.  
The results shown are means ± SEM of four to six different replicates. *p ≤ 0.05 when compared to CRL by Student’s t-test.
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the ATP synthase activity as determined in permeabilized cells 
(Figure  2F) resulting in a diminished cellular content of ATP 
(Figure 2G). However, it should be noted that the rates of aerobic 
glycolysis in IF1-cells can still be overstimulated by incubation 
with OL (Figure 2E), indicating that the overexpression of IF1 
is not enough to inhibit all the ATP synthase present in the cell. 
In agreement with previous reports (21, 27), the IF1-mediated 
inhibition of the ATP synthase resulted in a significant increase in 
basal cellular ROS levels (Figure 2H) without affecting the expres-
sion of other mitochondrial proteins (Figure  2I). Altogether, 
these results confirmed the biological activity of IF1 as a regulator 
of cellular energy metabolism in agreement with pre vious results.
iF1-Mediated gene expression
Analysis of the transcriptome of control (empty vector) and 
IF1-overexpressing breast cancer cells rendered 2,661 genes 
differentially expressed (p  ≤  0.05; fold change ≥1.5; LIMMA 
analysis) (Figure 3A; Table S1 in Supplementary Material). From 
the global list of significant genes (Table S1 in Supplementary 
Material), 1,427 were upregulated and 1,234 were downregulated 
(Figure 3A). A volcano plot that combines the statistical signifi-
cance with the magnitude of change illustrates the distribution of 
the IF1-regulated genes further emphasizing some of the genes 
that display large magnitude of significant change (Figure 3B). 
Consistently, the ATPIF1 gene was found significantly overex-
pressed in the transcriptome of IF1-cells (Figure 3B). A pathway 
enrichment analysis using the GeneCodis tool (42) against KEGG 
and Panther pathways databases highlighted that most of the 
affected pathways on IF1-cells were related to cancer (Figure 3C). 
In the case of KEGG database, the affected pathways revealed 
association with the ECM (focal adhesion, ECM–receptor inter-
action, and regulation of actin cytoskeleton), intercellular com-
munication (cytokine–cytokine receptor interaction and MAPK 
signaling, calcium signaling, and chemokine signaling pathways), 
and cell cycle (Figure 3C). In the case of Panther database, similar 
groups appeared with the addition of angiogenesis and apoptosis 
(Figure 3C). Moreover, we performed an additional enrichment 
analysis with IPA ingenuity tool in order to complement the 
information with a prediction of the activation/repression status 
of the affected pathways. The results obtained pointed out that 
the majority of the canonical pathways affected in IF1-cells were 
related to cancer (Figure 3D) and, more specifically, to cellular 
mobility/metastasis and tumorigenesis in agreement with the 
previous enrichment analysis. Remarkably, these functions were 
predicted to be inhibited in IF1-cells when compared to controls 
(Figure 3D). Moreover, the IPA analysis of diseases and functions 
highlighted that migration and invasion of breast cancer cells were 
specifically inhibited in IF1-overexpressing cells (Figure  3E). 
Overall, these results suggest that IF1 overexpression could favor 
the generation of a cellular phenotype with less mobility and 
invasiveness, which could underpin the lower metastasis and 
better prognosis of breast cancer patients bearing tumors with 
high expression level of the protein.
Tables S2 and S3 in Supplementary Material list the 52 upre-
gulated and 79 downregulated genes in IF1-cells when compared 
to controls that meet the more restrictive multiple correction test 
of Bonferroni (Figure 4A). Pathway enrichment analysis using 
the GeneCodis tool with the set of 138 genes also confirmed that 
cellular movement and cell-to-cell signaling and interaction are 
affected in IF1-overexpressing breast cancer cells.
iF1 Overexpression affects the  
expression of ecM-related Players
The results of the transcriptomic analysis were validated by the 
quantification of the expression of some of the genes involved 
in ECM and its signaling by quantitative PCR (Figure  4B). 
Consistently, SERPINB7 and SERPINB11, which are members 
of the superfamily of inhibitors of extracellular proteases, were 
highly up regulated in IF1-cells (Figure 4B). On the other hand, 
a significant diminished expression of ACTA2, encoding a mem-
ber of the actin protein family important for cell movement and 
contraction; POSTN which encodes periostin—a component of 
the ECM involved in the organization of collagens; and VCAN—a 
member of the versican proteoglycan family which is involved in 
cell adhesion, were found downregulated in IF1-overexpressing 
cells (Figure 4B). Likewise, the expression of signaling molecules 
such as the cytokine TGFB3, which is involved in the regulation 
of cell adhesion, of the ECM, and of WNT2B (formerly WNT13), 
encoding a glycoprotein of the wingless secreted signaling fac-
tors that promote epithelial–mesenchymal transition (EMT), 
was significantly downregulated in IF1-overexpressing cells 
(Figure 4B). Overall, these results support that a low expression 
of IF1 in breast cancer cells favors remodeling of the ECM to 
facilitate cellular migration and metastasis.
Next, we studied by immunoblotting the expression of some 
proteins commonly associated with the modification of the 
ECM, the induction of EMT, and cell migration. The results 
revealed no differences in vimentin or β-catenin levels between 
control and IF1-overexpressing cells (Figure 4C). Likewise, the 
NF-κB and Snail pathways—two pathways frequently activated 
FigUre 3 | Transcriptome of breast cancer inhibitory factor 1 (iF1)-overexpressing cells. (a) Representation of the total number of significantly affected 
genes by IF1 overexpression when compared to controls using Agilent 8x60K Human arrays. (B) Volcano plot with some relevant genes indicated. X axis represents 
the expression fold change of the affected genes, and the Y axis represents −log10 of the FDR values. (c) Gene enrichment analysis, showing the information 
related to KEGG and Panther databases. (D,e) Pathways (D) and diseases and functions (e) affected by IF1 overexpression as revealed by the IPA ingenuity  
tool. Z-score indicates the overall predicted activation/inhibition state of the function. CP, other cancer processes (glioblastoma multiforme signaling).
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in cancer—were not significantly affected by the overexpression 
of IF1 in breast cancer cells (Figure 4C). However, the levels of 
E-cadherin, an adhesion molecule involved in the maintenance 
of cellular and epithelial tissue integrity, was significantly 
upregulated in IF1-overexpressing cells (Figure 4C). Furthermore, 
integrin-β1—an adhesion molecule related to migration, extrava-
sation, and metastasis (44)—levels were found significantly 
upregulated in control when compared to IF1-overexpressing cells 
FigUre 4 | Breast cancer inhibitory factor 1 (iF1)-overexpressing cells have a less migratory and invasive phenotype. (a) The heatmap shows the 
transcriptome of the 138 differentially expressed genes between control (CRL) and IF1-overexpressing cells that meet the Bonferroni correction. Four different 
samples of each cell type (CRL and IF1) were included in the Agilent 8x60K Human arrays. (B) Quantitative reverse transcription PCR validation of up and 
downregulated genes in the microarray analysis in CRL (closed bars) and IF1-overexpressing (gray bars) cells. (c) Protein expression of extracellular matrix  
and epithelial–mesenchymal transition-related factors detected by immunoblotting. (B,c) The histograms show the quantification of mRNA (B) and protein  
(c) expression as the means ± SEM. *p ≤ 0.05 when compared to CRL by Student’s t-test.
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(Figure 4C). Overall, the results reveal that the overexpression of 
IF1 in breast cancer cells supports the maintenance of ECM and 
tissue integrity.
iF1-Overexpressing BT549 cells have 
less Tumorigenic and Migration capacity
Assessment of the rates of cellular proliferation (Figure  5A) 
and of cell death after hydrogen peroxide or STS treatment 
(Figure 5B) revealed no relevant differences between control and 
IF1-express ing cells. Interestingly, soft agar colony-formation 
assays showed that IF1-cells had a significant less capacity to 
grow and form colonies in the anchorage-independent assay 
(Figure 5C), suggesting a lower tumorigenic potential. To verify 
the migration ability of the cells, wound healing assays were 
carried out (Figure 5D). The results revealed that control cells 
started filling and fully occupied the scratched area earlier than 
IF1-cells (Figure 5D; see Video S1 in Supplementary Material), 
indicating that IF1-overexpressing cells had less migration ability 
than control cells. Similarly, matrigel invasion assays also revealed 
that control cells had a higher invasive capacity than IF1-cells 
FigUre 5 | Breast cancer inhibitory factor 1 (iF1)-overexpressing (gray line and bars) cells are more vulnerable and migrate and invade less than 
control (crl, black and closed bars) breast cancer cells. (a) Cellular proliferation at 24, 48, and 72 h. (B) Cell death after 24 h of priming the cells with 1 µM 
staurosporine (STS) or 120 µM hydrogen peroxide. *p < 0.01 when compared to non-treated by Student’s t-test. (c) Representative images of the anchorage-
independent growth in soft agar. (D) Representative time frames of the wound healing video assays. (e) Representative images of the matrigel invasion assays  
at 48 and 72 h. The histograms (c,D) and graph (e) show the quantification as the means ± SEM; *p ≤ 0.05 when compared to CRL by Student’s t-test.
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(Figure 5E). Overall, these results suggest that IF1 overexpres-
sion in breast cancer cells induces a less aggressive phenotype 
by diminishing the migration and invasive capacities of the cells. 
This finding agrees with the fact that breast cancer patients with 
elevated tumor levels of IF1 had less metastatic disease.
DiscUssiOn
Triple-negative breast cancers are defined as tumors that lack 
expression of estrogen receptor, progesterone receptor, and HER2 
(45). Triple-negative carcinomas represent 15–20% of tumors 
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in women with breast cancer, have a relatively poor outcome, 
and are refractory to hormone and epidermal growth factor 
receptor type 2 (HER2) therapies (45). Herein, we report that the 
overexpression of IF1 in human breast carcinomas, especially 
in the subgroup of triple-negative breast carcinomas predicts a 
lower risk for metastatic disease (21). This finding is counterin-
tuitive since (i) the overexpression of IF1 inhibits mitochondrial 
respiration and enhances glycolysis, which is a metabolic phe-
notype that is enforced in proliferating invasive cells (2, 3, 5, 6), 
(ii) a high expression level of IF1 has been recently reported 
as biomarker of bad prognosis in human hepatocarcinomas 
(28) and in carcinomas of the lung (29), bladder (30), and 
stomach (31) and in gliomas (32), and (iii) the overexpression 
of IF1 in the liver of transgenic mice significantly contributes 
to an increase in hepatocarcinogenesis (46). To investigate the 
molecular mechanisms that might support the “non-canonical” 
behavior of IF1 in breast cancer, which might open up potential 
new trends in diagnosis and treatment of breast cancer patients, 
we developed the triple-negative breast cancer BT549-luc cell 
line that stably overexpresses IF1. Consistent with previous 
results in transient transfection experiments in breast cancer 
cells (21), we show that stably overexpressing IF1-cells par-
tially suppressed respiration, induced aerobic glycolysis, and 
showed and enhanced basal ROS levels when compared to 
control cells. Transcriptomic analysis suggested that IF1-cells 
have a less aggressive phenotype when compared to controls 
because they concertedly upregulate the expression of genes 
involved in repression of ECM dismantling and overexpress 
genes that support ECM. These findings have been validated 
at both the transcriptome and proteome levels and by in vitro 
cellular assays that illustrate that IF1-cells show a diminished 
ability for anchorage-independent growth and migratory and 
invasive capacities.
The overexpression of IF1 in prevalent human carcinomas 
including breast cancer has been shown to be unrelated to major 
changes in mRNA availability (21). Thus, the accumulation of IF1 
in breast carcinomas, which is a protein with very short half-life 
(21), should result from alterations in the synthesis and/or deg-
radation rates of the protein brought about by oncogenesis (21). 
Posttranslational modifications of IF1 could also contribute to the 
differential regulation of the turnover of the protein in cancer. 
In this regard, IF1 is a mitochondrial protein that experiences 
several posttranslational modifications such as phosphorylation, 
acetylation, glycosylation, and succinylation [for review, see 
Ref. (13)]. In the case of protein phosphorylation it renders 
a protein that is inactive as an inhibitor of the ATP synthase, 
because phosphorylation prevents IF1 binding to the enzyme 
(26) and, in most of the breast, colon, and lung carcinomas, 
analyzed IF1 is present in its dephosphorylated active form (26). 
Interestingly, the glycosylation of IF1 has also been described 
in breast carcinomas (43). Hence, we suggest that the study of 
IF1 turnover is a most relevant aspect of the pathophysiology of 
IF1 deserving a thorough future investigation in breast cancer.
In gastric (31) and bladder (30) cancer, an increased expres-
sion of IF1 has been shown to promote cellular proliferation. 
Likewise, the overexpression of IF1 in colon cancer cells triggers 
the transcriptional activation of the NF-κB pathway, thereby 
favoring proliferation and preventing cell death (27). Similarly, 
less apoptosis and an enhanced proliferation have been observed 
in induced hepatocarcinomas in transgenic mice overexpressing 
a constitutively active mutant of IF1 (46). Prevention of cell 
death by the overexpression of IF1 has also been observed 
in lung (21) and gastric (31) cancer cells. However, we show 
that the overexpression of IF1 in breast cancer cells has no 
significant impact in cellular growth and cell death response 
to STS and hydrogen peroxide. Interestingly, the overexpres-
sion of IF1 in hepatocarcinomas (28) and in gliomas (32) 
also promotes the activation of the NF-κB pathway that, by 
triggering the activation of Snail favors EMT and hence cel-
lular migration and invasion. However, breast cancer IF1-cells 
did not show any relevant activation of the NF-κB and Snail 
pathways. Moreover, no relevant changes were observed in the 
expression of β-catenin and vimentin, respectively, representing 
epithelial and mesenchymal markers. In fact, breast cancer IF1-
overexpressing cells provided a phenotype completely opposite 
to that summarized above for other cancer cells. The phenotype 
of IF1-cells is compatible with the inhibition of cell migration 
and the maintenance of the ECM. Consistently, members of the 
Serpin B clade are overexpressed in IF1-cells being some of its 
members directly related with suppression of migration and 
invasion in breast cancer (47), whereas its downregulation is 
associated with the aggressiveness of squamous cell carcinomas 
(48, 49). On the other hand, (i) ACTA2 which has been related 
to increased cell motility in breast cancer and other cancer types 
(50, 51), (ii) POSTN, a protein secreted by cancer cells that 
has been described to facilitate cell motility and was recently 
purposed as an interesting target for prevention and treatment 
of breast tumor metastasis (52, 53), and (iii) VCAN, known to 
enhance tumorigenesis and cell mobility, invasion, and survival 
of breast tumors (54), are all dramatically silenced in IF1-
overexpressing breast cancer cells. Besides, we found that IF1 
overexpression increased the presence of the epithelial marker 
E-cadherin involved in maintenance of cell and epithelial tissue 
integrity and inversely correlated with invasion and metastasis 
(55, 56). Furthermore, integrin β1 an adhesion molecule (55) 
related to migration, extravasation, and metastasis (44) is found 
significantly reduced in IF1-cells. Therefore, IF1 overexpression 
in breast cancer cells seems to promote the maintenance of ECM 
and tissue integrity diminishing their tumorigenic potential in 
agreement with the observed less migrating and invasive pheno-
type and consistent with the observation that IF1 overexpression 
is a biomarker of better prognosis in breast cancer patients (21). 
Moreover, our findings are also consistent with the idea that 
metastatic breast cancer cells are those with low IF1 expression 
level, in agreement with the observation that IF1 expression is 
significantly reduced in lymph node metastasis when compared 
to the primary tumors (43).
Growth in soft agar, wound healing, and matrigel invasion 
assays are in  vitro approaches to assess the transformation 
potential of the cells by determining its anchorage-independent 
ability to grow or the cellular motility and invasiveness, which are 
related to the metastatic ability of neoplastic cells. Unfortunately, 
the BT549-luc cell line did neither develop orthotopic tumors nor 
gave rise to metastatic disease after tail vein injection when the cells 
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were implanted into nude mice to assess tumor growth and meta-
static potential in vivo. Therefore, the underlying IF1-mediated 
regulatory mechanism promoting tissue integrity in breast cancer 
in vivo remains to be elucidated. However, we suggest that TGF-β 
and Wnt signaling pathways whose activation is complex and 
known to promote EMT in different carcinomas including ovar-
ian and breast cancer (57, 58), and highlighted in this study as 
downregulated in the transcriptomic analysis, might play a role 
in this regard. Overall, these findings indicate that IF1 signaling 
is cell type specific and suggest that any potential cancer therapy 
using IF1 as a target should be tailored having this point into 
consideration.
In conclusion, our study confirms IF1 as a regulator of cellular 
energy metabolism that favors an enhanced glycolysis in breast 
cancer cells but, at variance with the findings reported for IF1 in 
other carcinomas, it promotes the maintenance of ECM avoiding 
metastatic disease. These results further provide a mechanistic 
explanation to the observed positive correlation existing between 
high IF1 levels in breast carcinomas and the lower metastasis 
observed in these patients. Overall, the findings strongly support 
a stringent tissue specific function for IF1 in cancer that should 
be taken into consideration when considering the development 
of future therapies using energy metabolism as a target for cancer 
treatment.
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